AbbVie (NYSE:ABBV) has announced that FDA has approved Skyrizi (risankizumab-rzaa) as the first interleukin-23 (IL-23) inhibitor to treat adults with moderately to severely active Crohn’s disease (CD).
Skyrizi is also FDA-approved as a treatment for moderate to severe plaque psoriasis and active psoriatic arthritis.
IL-23 inhibitors have surged in popularity recently, given their ability to treat diseases such as plaque psoriasis.
Janssen’s Stelara (ustekinumab), which inhibits both IL-12 and IL-23, has racked up the most indications. It is now FDA-approved for plaque psoriasis, psoriatic arthritis, Crohn’s disease and ulcerative colitis. Stelara was first FDA-approved in 2009.
Skyrizi is a newer drug, winning FDA approval for plaque psoriasis in 2019.
A 2019 analysis found that Skyrizi had higher efficacy than placebo and Stelara in treating moderate-to-severe chronic plaque psoriasis.